Company Description
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial.
In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD.
It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform.
The company was founded in 2005 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 160 |
| CEO | Linda Marbán |
Contact Details
Address: 10865 Road to the Cure, Suite 150 San Diego, California 92121 United States | |
| Phone | 858 727 1755 |
| Website | capricor.com |
Stock Details
| Ticker Symbol | CAPR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001133869 |
| CUSIP Number | 14070B309 |
| ISIN Number | US14070B3096 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Linda Marbán Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Frank Isaac Litvack FACC, M.D. | Executive Chairman of the Board |
| Anthony J. Bergmann M.B.A. | Chief Financial Officer and Corporate Treasurer |
| Karen G. Krasney Esq., J.D. | Executive Vice President, General Counsel and Secretary |
| Dr. Kristi A. H. Elliott Ph.D. | Chief Science Officer |
| Minghao Sun Ph.D. | Senior Vice President of Research and Product Development |
| Mark Awadalla | Chief Development Officer |
| Catherine Lee Kelleher | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2025 | ARS | Filing |
| Apr 8, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2025 | 8-K | Current Report |
| Mar 26, 2025 | 10-K | Annual Report |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 30, 2025 | SCHEDULE 13G | Filing |
| Jan 2, 2025 | 8-K | Current Report |